Ac-LKKTETQ comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Delcy Rodríguez endorsed the agreement, saying it would have a "significant impact on our nation's revival" and generate more than $200 billion in tax revenue for the government. The newspaper reported that Chevron was separately in advanced talks to expand its own production in the country. It also reported that any meaningful new production would take years to materialise, so the agreement would have little immediate effect on global commodity prices or on what United States consumers pay for fuel; Venezuela was producing a little over one million barrels a day, about one per cent of global output and roughly the same share as under Maduro. The announcement followed earlier reports that the Trump administration had been in advanced negotiations to acquire a direct stake in Venezuelan oilfields. These reports had already generated unease among members of Venezuela's opposition. One opposition figure, speaking anonymously due to the sensitivities of criticizing the United States, described the proposed arrangement as "a land grab – a massive land grab," adding that it was "revolting" and represented "a rapacious, mafioso United States," in contrast to the United States of the Marshall Plan. Ricardo Hausmann, a former Venezuelan minister in exile and opposition supporter, wrote on X that an illegitimate interim government lacked the legitimacy to sign what he termed an unconstitutional agreement, and predicted that it would fail for all parties involved.
== Similar species == The distinguishing features of Parmotrema perlatum, such as the presence of soredia and stictic acid, facilitate its easy identification. In mature specimens, the appearance of scattered, fine cracks on the upper surface may resemble the cracked maculae seen in P. reticulatum, which shares similar habitats. However, the two species can be differentiated chemically, as P. reticulatum contains salazinic acid, unlike P. perlatum. Parmotrema perlatum and Parmotrema stuppeum are two morphologically similar species that can be found in similar habitats. Both species have a loosely attached thallus with revolute, wavy lobes and sparsely ciliate lobe tips. Their upper cortex is continuous and not finely reticulately cracked, while the lower surface is black and rhizinate. Both species also feature linear soralia. However, there are several key differences that can help distinguish between the two. While earlier descriptions suggested that P. stuppeum has a matte, olive-green to brownish-green upper surface and P. perlatum has a slightly shiny, whitish-grey to greyish-green upper surface, recent observations have shown that both species have a distinctly matte upper surface with similar colouration. The most reliable morphological difference in the field is the location of the soralia: P. stuppeum has strictly terminal soralia, whereas P. perlatum has submarginal soralia. Additionally, the two species can be distinguished by their chemical composition. P. stuppeum contains salazinic acid, while P. perlatum has a stictic acid complex.
=== Pregnancy and breastfeeding === The safety of using omeprazole has not been established in pregnant or breastfeeding women. Epidemiological data do not show an increased risk of major birth defects after maternal use of omeprazole during pregnancy.
Silk has been used to close wounds for centuries. By the 19th and 20th centuries it had become one of the standard suture materials in Western surgery—strong, easy to handle and reliable at holding a knot—and braided silk remained in use long after many other natural threads had given way to synthetics. The field in its current form began with a straightforward idea: silk could be broken down and then reassembled into a new form. Dissolving degummed fibres in a concentrated salt solution yields a water-based fibroin liquid that can be cast, spun or gelled. This regenerated silk, rather than the woven fibre, is the basis of most silk biomaterials. The methods for preparing the solution and converting it into films, sponges and hydrogels were established in the late 1990s and 2000s, much of the work carried out at Tufts University in the United States. A 2010 review in Science described how regenerated silk had extended beyond textiles and sutures into optics, electronics and tissue engineering, and helped establish its reputation as a material that can be processed from water under mild conditions. The first engineered silk devices received regulatory clearance in the same period, marking the point at which laboratory research began to yield commercial products.
=== Mixtures === Typically, supercritical fluids are completely miscible with each other, so that a binary mixture forms a single gaseous phase if the critical point of the mixture is exceeded. However, exceptions are known in systems where one component is much more volatile than the other, which in some cases form two immiscible gas phases at high pressure and temperatures above the component critical points. This behavior has been found in systems such as N2-NH3, NH3-CH4, SO2-N2 and n-butane-H2O.. The systems composed by a supercritical fluid and a liquid are named Gas expanded liquids. The critical point of a binary mixture can be estimated as the arithmetic mean of the critical temperatures and pressures of the two components,
Sources: en.wikipedia.org
In 1881, the Savoy Theatre in the City of Westminster, London was lit by Swan incandescent lightbulbs, which was the first theatre, and the first public building in the world, to be lit entirely by electricity. The first street in the world to be lit by incandescent lamps was Mosley Street, Newcastle upon Tyne, United Kingdom in 1880.
== Reaction mechanism == In the first part of the reaction process, the carbonyl is converted to an iminium, to which a cyanide ion adds. First, the carbonyl oxygen of an aldehyde is protonated, followed by a nucleophilic attack of ammonia to the carbonyl carbon. After subsequent proton exchange, water is cleaved to form the iminium ion intermediate. A cyanide ion then attacks the iminium carbon yielding an aminonitrile.
Throughout the Cold War, Iraq had been an ally of the Soviet Union, and there was a history of friction between Iraq and the United States. The US was concerned with Iraq's position on Israeli–Palestinian politics. The US also disliked Iraqi support for Palestinian militant groups, which led to Iraq's inclusion on the developing US list of State Sponsors of Terrorism in December 1979.
== Synthesis == Big dynorphin is generated through the proteolytic processing of prodynorphin (PDYN), a 26-kilodalton precursor protein by proprotein convertase 1. The synthesis occurs within the neuronal cell body through translation of prodynorphin mRNA. Following translation, prodynorphin undergoes sequential processing by proprotein convertases, primarily PC1/3 and PC2, as well as the cysteine protease cathepsin L. Under normal circumstances, in the presence of carboxypeptidase E, prodynorphin is fully processed by sequential cleavage at dibasic amino acid sites to generate individual dynorphin peptides: dynorphin A1-17, dynorphin B, and α-neoendorphin. Big dynorphin forms when this proteolytic processing is incomplete, typically resulting from insufficient proprotein convertase activity or altered intracellular calcium levels during neurotransmitter release events. The 32-amino acid peptide comprises the complete dynorphin A sequence (residues 1-17) joined to the complete dynorphin B sequence, with two C-terminal amino acids.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.